medigraphic.com
ISSN 0035-0052 (Print)

2025, Number 1

<< Back Next >>

Rev Mex Pediatr 2025; 92 (1)

Bone density in patients with ADHD under methylphenidate treatment

García-Galicia A, Magallón-Ramírez D, Muñoz-Padrón B, Palacios-Figueroa D, Rodríguez-Palacios CL, Montiel-Jarquín ÁJ, Loria-Castellanos J, Bertado-Ramírez NR

Language: Spanish
References: 16
Page: 12-15
PDF size: 322.55 Kb.


ABSTRACT

Introduction: methylphenidate (MPH) is the most used drug for the treatment of pediatric patients with attention-deficit/hyperactivity disorder (ADHD), but its use has been linked to loss of bone mineral density (BMD). Objective: to compare BMD in pediatric patients with ADHD with and without MPH treatment. Material and methods: an observational, cross-sectional, comparative study conducted between June and August 2021 in a tertiary care hospital. BMD was assessed using DEXA (dual-energy X-ray absorptiometry). Statistical analysis included: Mann-Whitney U test, Fisher's exact test, and Spearman's rho test. Results: thirty-two patients were included, 18 males (56.3%), aged 6 to 16 years. Of the total, 15 were receiving MPH and 17 were not. No differences were found in BMD z-scores between the two groups (p = 0.55), nor in the proportion of low BMD (23.5 vs 20%, p = 0.80). Correlation between the duration of MPH treatment and the BMD z-score was not statistically significant (Rho = −0.05, p = 0.77). Conclusions: in this study, no relationship was demonstrated between the use and duration of MPH treatment and BMD in pediatric patients with ADHD.


REFERENCES

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington (VA): American Psychiatric Association Publishing; 2013. doi: 10.1176/appi.books.9780890425596.

  2. Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020; 395(10222): 450-462. doi: 10.1016/S0140-6736(19)33004-1.

  3. Oliveira VFL de, Moreira DJS, Fonseca JB da, Rossi K, Vasconcelos SS dos, Dias CAG de M et al. Metilfenidato: una revisión. Revista Científica Multidisciplinar Núcleo do Conhecimento. 2021; 6(5): 5-14. Disponible en: http://dx.doi.org/10.32749/nucleodoconhecimento.com.br/salud/metilfenidato-una-revision

  4. Wilens TE. Effects of methylphenidate on the catecholaminergic system in Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmacol. 2008; 28(3): S46-S53. doi: 10.1097/JCP.0b013e318173312f.

  5. Kis B, Lücke C, Abdel-Hamid M, Hebmann P, Graf E, Berger M et al. Safety profile of methylphenidate under long-term treatment in adult ADHD patients – results of the COMPAS study. Pharmacopsychiatry. 2020; 53(6): 263-271. doi: 10.1055/a-1207-9851.

  6. Kirkland-Lawson S. Mind over matter: stimulant ADHD medication use and bone mineral density in college-aged subjects; Is there a trade-off? [Thesis]. Huntsville, AL: The University of Alabama in Huntsville; 2019.

  7. Fu Y, Wang G, Liu J, Li M, Dong M, Zhang C et al. Stimulant use and bone health in US children and adolescents: analysis of the NHANES data. Eur J Pediatr. 2022; 181: 1633-1642. doi: 10.1007/s00431-021-04356-w.

  8. Zhong XP, Xia WF. Regulation of bone metabolism mediated by β-adrenergic receptor and its clinical application. World J Clin Cases. 2021; 9(30): 8967-8973. doi: 10.12998/wjcc.v9.i30.8967.

  9. Kamal M, Bener A, Ehlayel MS. Is high prevalence of vitamin D deficiency a correlate for attention deficit hyperactivity disorder? Atten Defic Hyperact Disord. 2014; 6(2): 73-78. doi: 10.1007/s12402-014-0130-5.

  10. Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B et al. Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev. 2019; 40(4): 1109-1151. doi: 10.1210/er.2018-00126.

  11. Dursun S, Sezen-Erhamza T, Onder ME, Erdogan-Düzcü S. Effect of methylphenidate at different doses on new bone formation with rapid maxillary expansion: a micro-CT and histomorphometric study in rats. Orthod Craniofac Res. 2022; 25(3): 384-392. doi: 10.1111/ocr.12547.

  12. Lee Y, Kong N, Koo S, Bai DS, Kim HJ, Jeong H et al. A 24-month effects of methylphenidate use on growth in children and adolescents with attention deficit hyperactivity disorder. Psychiatry Investig. 2022; 19(3): 213-219. doi: 10.30773/pi.2021.0309.

  13. Carucci S, Zuddas A, Lampis A, Man KKC, Balia C, Buitelaar J et al. The impact of methylphenidate on pubertal maturation and bone age in ADHD children and adolescents: results from the ADHD Drugs Use Chronic Effects (ADDUCE) project. J Atten Disord. 2024; 28(5): 722-739. doi: 10.1177/10870547241226726.

  14. Li Q, Zhou J. Influence of dietary patterns and physical activity on bone mineral content and density, osteoporosis among children with stimulant use. Front Pediatr. 2022; 10: 976258. doi: 10.3389/fped.2022.976258.

  15. Iconaru L, Moreau M, Kinnard V, Baleanu F, Paesmans M, Karmali R et al. Does the prediction accuracy of osteoporotic fractures by BMD and clinical risk factors vary with fracture site? JBMR Plus. 2019; 3(12): e10238. doi: 10.1002/jbm4.10238.

  16. Schermann H, Ankory R, Shlaifer A, Dolkart O, Rotman D, Yoffe V et al. Lower risk of stress fractures in young adults with ADHD under chronic treatment with methylphenidate. Bone. 2019; 120: 20-24. doi: 10.1016/j.bone.2018.09.023.




2020     |     www.medigraphic.com